Dr. Westin on Challenges With Precision Medicine in Endometrial Cancer

Shannon N. Westin, MD, MPH, clinical investigator and director of Early Drug Development and Phase I Trials in the Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, discusses challenges with precision medicine in endometrial cancer. 

Despite encouraging data ​with combination ​regimens such as lenvatinib (Lenvima) and pembrolizumab (Keytruda), ​toxicity remains a challenge, says Westin.

​However, this does not mean that chemotherapy is the better alternative, ​she adds.

Precision medicine shows promise in the endometrial cancer space ​and research efforts are aimed at developing strategies to mitigate or prevent treatment-related adverse effects (AEs), ​Westin says.

Often, patients​ who experience AEs may want to stop treatment, even if the regimen is working. Finding a way to mitigate AEs will help patients remain on effective therapies, Westin concludes.